

Sachs Associates in association with Bloomberg L.P.

**4th Annual
NORTH AMERICA FORUM FOR
INVESTING & PARTNERING
IN BIOTECH AND MEDTECH**

16 – 17 March 2005, Fairmont Copley Plaza, Boston, MA

AGENDA, Wednesday 16th March			
8.00	Registration		
9.00	BALLROOM: Chairman's Welcome Address: Kathleen Williams, Co-Chair, Life Sciences, Palmer & Dodge		
9.15 - 9.35	Keynote: Life Science Start-ups: Exploring the Adjacent Probable Dr Noubar B. Afeyan, Senior Managing Director & CEO, Flagship Ventures		
9.35 - 9.55	Keynote Address: Bio Defense: recognising the need for new therapeutics Dr Ansbert Gadicke, Founding General Partner & Chairman, MPM Capital		
9.55	Coffee Break		
10.20 - 12.30	Small-Cap Listed Company Presentations		
	Ballroom: SMALL CAP LISTED COMPANIES Chair: Dr John Burt, Thiakis	Venetian Room: SMALL CAP LISTED COMPANIES Chair: Rich Smith, Palmer & Dodge	Ballroom Foyer: SMALL CAP LISTED COMPANIES Chair: Yvonne Wegmann, SWX Swiss Exchange
10.25	MethylGene, Inc. Donald F. Corcoran, President & CEO	Avitar Peter Phildius, Chairman & CEO	Emisphere Technologies Inc Dr Michael M Goldberg, Chairman & CEO
10.40	BioSante Pharmaceuticals Stephen Simes, CEO	Norwood Abbey Bernie Romanin, Senior Vice President Corporate Development	Favrille John Longenecker, President & CEO
10.55	MacroChem Robert DeLuccia, President & CEO	Biophan Technologies Michael Weiner, CEO	Basilea Pharmaceutica Dr Anthony Man, CEO
11.10	Palatin Technologies Dr Carl Spana, President & CEO	Life Medical Sciences Robert P. Hickey, President & CEO	Diamyd Medical Anders Essen-Moller, President
11.25	Grant Life Sciences Stan Yakatan, CEO	Viventia Biotech Dr Nick Glover, President & CEO	VioQuest Brian Lenz, CFO
11.40	YM Biosciences David Allan, Chairman	NovoDel Pharma Dr Gary A. Shangold, President & CEO	Zeltia Catherine Moukheibir, Director Capital Market Operations & Jose Jimeno, VP Scientific Development

11.55	Curis Daniel Passeri, President & CEO	Adherex Technologies Dr William Peters, Chairman & CEO	
12.10	Questions	Questions	Questions
12.15	Lunch		
13.45 - 14.05	Keynote Address Stelios Papdopoulos, Vice Chairman, SG Cowen Securities Corporation		
14.05 - 14.20	Keynote: Overview of the European Capital Markets Dr Heinrich Henckel, CEO, SWX Swiss Exchange		
14.20 - 14.35	Keynote: Biotech Investing, now and then Jean-François Formela, Senior Partner, Atlas Venture		
14.35	Coffee Break		
15.05 - 17.10	Venture Funded Early to Mid Stage Company Presentations		
	<u>Ballroom:</u> IMMUNOLOGY/ONCOLOGY Chair: Rhonda Chiger, RX IR Communications	<u>Venetian Room:</u> THERAPEUTICS Chair: Donna LaVoie, LaVoie Strategic Communications Group	<u>Ballroom Foyer:</u> THERAPEUTICS Chair: Patrick
15.10	Avidex James Noble, CEO	Aderis Pharmaceuticals Kenneth L. Rice, CFO & Chief Commercial Officer	atugen Thomas Christély, COO & CFO
15.25	ESBAtech Dr Dominik Escher, CEO	Serenex Dr Richard Kent, CEO	DeveloGen Dr Guenther Karmann, CEO
15.40	BioVex Dr Tony Mills, VP Business Development	ACE Biosciences Ingelise Saunders, CEO	EVOTEC Neurosciences Dr John Kemp, CEO
15.55	TransMolecular Dr Matthew Gonda, President & CEO	Psychiatric Genomics Dr Richard Chipkin, President & CEO	Sirtris Dr Christoph Westphal, CEO
16.10	Oncomethylome Sciences Dr Herman Spolders, CEO	Ambit Biosciences Scott Salka, CEO	PBL Therapeutics Robert Pestka, President & CEO
16.25	Intercell Prof Alexander von Gabain, CEO	Lipocine Jerry Simmons, Corporate Business Development Officer	MedExGen Dr Yong-Hoon Chung, President & CEO
16.40	Aegera Therapeutics Inc Michael Atkin, CEO	NeuroMed Technologies Dr Christopher C. Gallen, President & CEO	
17.05	Cocktail Reception hosted by The American Stock Exchange		

Sachs Associates in association with Bloomberg L.P.

**4th Annual
NORTH AMERICA FORUM FOR
INVESTING & PARTNERING
IN BIOTECH AND MEDTECH**

16 – 17 March 2005, Fairmont Copley Plaza, Boston, MA

AGENDA, Thursday 17th March	
8.00	Registration
8.45	BALLROOM: Chairman's Welcome Address: Mark R. Saunders, President, Global Markets Capital Group LLC
9.00 - 9.45	Panel Discussion: Venture Financing the way forward Chair: Martin Lytton, General Partner, Oxford Bioscience Partners Discussants: Dr Christoph Westphal, General Partner, Polaris Venture Partners Jonathan Leff, Managing Director, Warburg Pincus James M Garvey, CEO & Managing Partner, Schroder Ventures Life Sciences
9.45 - 10.00	Keynote Address G. Steven Burrill, CEO, Burrill & Company
Venture Funded Early to Mid Stage Company Presentations	
10.05	Ballroom: IMMUNOLOGY/ONCOLOGY Chair: Dr Anil Khurana, Access International
10.20	Aureon Biosciences Corporation Vijay Aggarwal, CEO & President
10.35	Librophyt Alain Tissier, CEO
10.50	Pieris ProteoLab Dr Martin Poelchen, CEO
11.05	Topigen Pharmaceuticals Dr Paul Wotton, President & CEO
11.20	Xanthus Dr Richard Dean, CEO
11.35	Bioxalis Medica
11.50	POST GENOMICS Iconix Jim Neal, CEO
	Venetian Room: THERAPEUTICS Chair: Christine Labaree, The Trout Group
	Amphora Discovery Corporation Peter G. Savas, Chairman of the Board
	BioLine RX Dr Morris Laster, CEO
	Medicago Andy Sheldon, President & CEO
	TransPharma Medical Dr Daphna Heffetz, CEO
	Scil Technology Dr Irina Staatz-Granzer, Managing Director
	Arrow Therapeutics Ian Garland, CFO
	PolyMedix Nick Landekic, President & CEO

12.05	Perlegen Robert Middlebrook, Chief Corporate Development Officer	
12.25	Lunch	
13.45 - 15.00	Panel Discussion: Why is Medtech attracting new investment Chair: William C Mills III, Managing Member, EGS Healthcare Capital Partners Discussants: Chuck Hadley, Managing Director, Rock Hill Ventures Marc Goldberg, Managing Director, BioVentures Investors Jan Wald, Analyst, AG Edwards & Sons Dr Lothar Krinke, Senior Director BioSciences Technology Department, Medtronic Mark Chalek, Chief, Business Ventures, Beth Israel Deaconess Medical Centre	
15.00 - 16.00	Panel Discussion: Bio Partnering and Collaborations between Pharmas and Biotechs Chair: Dr Maggie Flanagan, Global Alliance Director, Enabling Science & Technology, AstraZeneca Discussants: Dr Klaus Wilgenbus, Head of Corporate Division, Licensing, Boehringer Ingelheim Dr Robert Gould, Vice President, External Scientific Affairs Worldwide, Merck & Co Steve Twait, Alliance Management, Eli Lilly & Co Dr Maggie Flanagan, Global Alliance Director, Enabling Science & Technology, AstraZeneca	
16.00 - 16.15	Concluding Presentation: Global Themes – Looking ahead to 2006 and beyond Stan Yakatan, Chairman, Katan Associates	
16.20	Close of Conference	